Understand the source comparison
Peptides for Eczema: Clinical Evidence Comparison
KPV (Lys-Pro-Val) Melanocortin receptor agonist. Inhibits NF-κB nuclear translocation 40–60% reduction in IL-6, TNF-α expression in vitro; 32% TEWL reduction in dermatitis models (University of Arizona) Topical, twice daily for 8–12 weeks Most direct evidence
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- KPV (Lys-Pro-Val)
- Melanocortin receptor agonist. Inhibits NF-κB nuclear translocation
- 40–60% reduction in IL-6, TNF-α expression in vitro; 32% TEWL reduction in dermatitis models (University of Arizona)
- Topical, twice daily for 8–12 weeks
- Most direct evidence for cytokine modulation in atopic inflammation
- LL-37 (Cathelicidin)
- Antimicrobial membrane disruption + LPS/LTA neutralisation
- 68% reduction in S. aureus colonisation after 7 days (Karolinska Institutet)
- Topical, once daily to lesional skin
- Best option for eczema with confirmed bacterial superinfection
- Thymosin Beta-4
- VEGF upregulation, keratinocyte migration, MMP activation
- 28% faster wound closure in barrier-compromised skin (Wound Repair and Regeneration)
- Topical, twice daily to lichenified areas
- Strongest evidence for structural barrier repair in chronic lesions
- GHK-Cu (Copper Peptide)
- Collagen synthesis stimulation, TGF-β activation
- Increased procollagen I/III synthesis by 70% in fibroblast cultures
- Topical, once daily as maintenance therapy
- Preventive/maintenance use. Less acute anti-inflammatory data